PARK7 and Parkinson disease: Proteins known to be involved in Alzheimer’s disease progression, (such as CLU, APOE, and ADAM10) and Parkinson’s Disease (such as PARK7 and VPS35) were also identified [48,49,50,51], suggesting a potential role of GDE2-released EVs in neurodegeneration (Figure 5C, Tables S1 and S3).